The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brode, S.
Right arrow Articles by Cooke, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brode, S.
Right arrow Articles by Cooke, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYCLOPHOSPHAMIDE
Medline Plus Health Information
*Diabetes Type 1
The Journal of Immunology, 2006, 177: 6603-6612.
Copyright © 2006 by The American Association of Immunologists, Inc.

Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells1

Sven Brode2, Tim Raine2, Paola Zaccone and Anne Cooke3

Department of Pathology, University of Cambridge, Cambridge, United Kingdom


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Regulatory T cells (Tregs) have been implicated as key players in immune tolerance as well as suppression of antitumor responses. The chemotherapeutic alkylating agent cyclophosphamide (CY) is widely used in the treatment of tumors and some autoimmune conditions. Although previous data has demonstrated that Tregs may be preferentially affected by CY, its relevance in promoting autoimmune conditions has not been addressed. The nonobese diabetic mouse spontaneously develops type-1 diabetes (T1D). We demonstrate in this study that CY targets CD4+CD25+Foxp3+ Tregs in vivo. CD4+CD25+ T cells isolated from CY-treated mice display reduced suppressive activity in vitro and increased expression of apoptotic markers. Although Treg numbers rapidly recovered to pretreatment levels in the peripheral lymphoid tissues, Tregs failed to recover proportionally within pancreatic infiltrates. T1D progression was effectively prevented by adoptive transfer of a small number of islet Ag-specific CD4+CD25+ Tregs to CY-treated recipients. Prevention of T1D was associated with reduced T cell activation and higher Treg proportions in the pancreas. We conclude that acceleration of T1D by CY is associated with a reduction in CD4+CD25+Foxp3+ Tregs and can be prevented by transfer of CD4+CD25+ Tregs.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Cyclophosphamide (CY)4 is a nitrogen mustard compound cytotoxic chemotherapeutic agent well-established in the treatment of chronic lymphocytic leukemias, lymphomas, and solid tumors, as well as an immunomodulatory agent. CY exhibits greatest cytotoxicity against cells actively replicating their DNA, as unpairing of DNA strands at this stage makes the nucleotide residues more susceptible to alkylation.

At high doses, CY prevents graft-vs-host disease during bone marrow transplantation and has sometimes been used as a disease-modifying agent in advanced, refractory rheumatoid diseases (1, 2), whereas, paradoxically, lower doses can lead to enhanced immune responses (3, 4) including those to tumors (5, 6, 7) and autoantigens (8, 9, 10).

Until recently, little was known about the molecular mechanism of CY-mediated immunomodulation. Studies in the 1980s showed that mice or rats given low-dose CY 2–3 days before sensitization displayed enhanced contact sensitivity or delayed-type hypersensitivity (11, 12, 13). Increased delayed-type hypersensitivity could be overridden by restoring the lymphoid compartment by administration of thymocytes after CY treatment (14). Administration of high-dose CY to prediabetic NOD mice leads to rapid synchronous onset of type-1 diabetes (T1D) (8), and transfer of mononuclear cells from syngeneic nondiabetic donors after CY treatment protects from T1D onset (15). These observations led to the proposal that CY causes a breakdown of regulatory networks by removal of a suppressor population (3, 10, 14, 16), although the nature of this cell type remained elusive until recently. Even though CY is cytotoxic to a number of lymphoid populations, in particular B cells (15, 17, 18), recent data has focused on its selective effect on CD4+CD25+ Tregs (19, 20, 21, 22).

CD4+CD25+ Tregs arise naturally from the thymus and represent a developmentally distinct T cell lineage that is characterized by a combination of surface markers including CD25, CD103, CTLA-4, CD62L, glucocorticoid-induced TNFR family related protein, as well as the expression of the X-linked forkhead/winged helix transcription factor (Foxp3) (23). Although several different kinds of regulatory T cells (Tregs) have been described, Foxp3+ Tregs have emerged as key players in the control of self-tolerance (24).

Selective effects of CY on CD4+CD25+ Tregs have been described in studies of tumor-bearing rats (22), mice (20), and humans (19) and can result in augmentation of antitumor responses. CD4+CD25+ Tregs display higher basal in vivo proliferation than CD4+CD25– T cells and result in a greater sensitivity to the cytotoxic effects of CY (20). In addition, Tregs isolated from CY-treated mice exhibited increased levels of apoptosis and their ability to suppress CD8+ T cell proliferation in vitro was abrogated. These recent findings have pointed toward a role of CY in ablating CD4+CD25+ Tregs in vivo, although the relevance of this to precipitating autoimmune conditions remains unknown.

Although CY may affect adaptive Treg function, for example, Tr1- and Th3-type cells, we have focused in this study on its effect on naturally arising Tregs. In this study, we demonstrate that CY results in the synchronous onset of T1D in prediabetic NOD mice accompanied by a reduction in naturally occurring CD4+CD25+Foxp3+ Tregs. In addition, CD4+CD25+ Tregs isolated shortly after CY treatment were found to be functionally impaired in their in vitro suppressive activity and displayed higher levels of apoptosis. We find that whereas cell numbers recover in lymphoid tissues immediately before onset of T1D, frequencies of Tregs in the pancreas remain low. The importance of Tregs in this model was further demonstrated by adoptive transfer of islet Ag-specific CD4+CD25+ Tregs from TCR-transgenic BDC2.5NOD mice which increased the frequency of pancreatic Tregs and suppressed T1D.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

NOD mice, transgenic GFP.NOD mice, BDC2.5.NOD TCR transgenic mice, and GFP.BDC2.5NOD TCR transgenic mice were housed and bred under specific pathogen-free conditions in the Pathology Department, University of Cambridge animal facilities (Cambridge, U.K.). GFP. BDC2.5.NOD mice were generated by crossing BDC2.5NOD mice and GFP.NOD mice, which were a gift from Dr. D. Kioussis (National Institute of Medical Research, London, U.K.). GFP protein expression is under the control of the CD2 promoter. C57BL/6 mice were purchased from Harlan, U.K. All animal work was conducted under U.K. Home Office project license regulations after approval by the Ethical Review Committee of the University of Cambridge.

Cyclophosphamide

CY (Endoxana) was obtained from Baxter Healthcare and prepared in 0.9% normal saline at 20 mg/ml immediately before i.p. administration.

T cell purification

For adoptive transfer and in vitro suppression assays, CD4+CD25– and CD4+CD25+ T cells were extracted from mice using the mouse CD4+CD25+ magnetic cell separation kit (Miltenyi Biotec) according to the manufacturer’s instructions. Cells were checked for purity by flow cytometry. Approximately 80% of CD4+CD25+ T cells stained positive for Foxp3, whereas purified CD4+CD25– cells contained <1% Foxp3+ cells.

Isolation of pancreatic-infiltrating leukocytes

Whole pancreas samples were harvested and processed from individual mice. Briefly, pancreases were torn into smaller pieces in cold PBS containing 5% FCS, 56 mM glucose, and Complete Mini Protease inhibitors (Roche). The tissues were washed twice in cold PBS, before incubation in 2 ml of prewarmed PBS containing 15% FCS and Liberase CI (Boehringer Mannheim). After digestion, tissues were washed and cell suspensions were prepared by forcing through a cell strainer. Suspensions were twice left to settle and the supernatants were decanted to remove stromal debris, before the cells were washed ready for use.

In vitro suppression assays

For analysis of the effects of CY on Treg cell function, CD4+CD25+ T cells were isolated from the pooled spleens of 10-wk-old male NOD mice treated as described above. CD4+CD25– cells were labeled by incubation in PBS with 5 µM CFSE (Molecular Probes) for 20 min at 37°C. Cells were then incubated in triplicate wells on a 96-well plate at 1 x 105/well with the indicated ratios of unlabeled CD4+CD25+ cells in the presence of 1 µg/ml anti-CD3 mAb and 5 x 105 irradiated splenocytes from male NOD mice. Proliferation of CD4+CD25– cells was assessed after 72 h by CFSE dilution. Alternatively, proliferation was assessed by incorporation of [3H]thymidine. A total of 1 µCi [3H]thymidine (Amersham Pharmacia Biotech) was added during the last 12 h of culture and incorporation detected using a beta-scintillation counter (Wallac).

Adoptive T cell transfers

Purified populations of CD4+CD25+ and CD4+CD25– T cells were prepared as described using magnetic sorting. For the analysis of the effects of polyclonal NOD Tregs in vivo, 2 x 106 purified NOD CD4+CD25+ cells, or CD4+CD25– cells were transferred i.v. into 10-wk-old male NOD mice given 200 mg/kg 24 h previously. For the analysis of the effects of islet Ag-specific BDC2.5NOD or GFP.BDC2.5NOD Tregs, CY-treated NOD mice received from 1 x 105 to 2 x 106 purified T cells i.v. at the indicated time point after CY administration. All recipient mice were then studied for T1D incidence, or sacrificed for analysis of the distribution of GFP+ cells.

Flow cytometric analysis

Single-cell suspensions were prepared from various organs as described above. Cells were washed and resuspended in staining buffer (PBS, 1% FCS, and 0.05% NaN3) before staining with appropriate combinations of FITC, PE, PerCP, or allophycocyanin conjugates (all obtained from BD Pharmingen) of Abs to the following cell surface markers (hybridoma clone indicated in parentheses): CD3 (2C11), CD4 (L3T4), CD8{alpha} (53–6.7), CD11b (M1/70), CD11c (HL3), CD19 (1D3), CD25 (PC61), CD62L (MEL-14), and CD44 (IM7). Appropriate isotype control Abs were included.

Intracellular Foxp3 staining was performed according to the manufacturer’s instructions (Foxp3 anti-mouse/rat Foxp3 staining set; eBioscience). For visualization of intracellular GFP together with Foxp3, the fix/perm step was shortened to 1 h.

Cells were acquired using a BD LSR I flow cytometer (BD Biosciences) and analyzed using FlowJo (Tree Star) software.

Apoptosis

Staining for apoptosis was conducted on single-cell suspensions of spleen and pancreatic lymph node (PLN) cells. Briefly, single-cell suspensions were prepared in complete medium and cells were washed in binding buffer (10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM CaCl2). A total of 1 x 106 cells were incubated for 15 min at room temperature with Annexin VFITC (1/20 dilution) (BD Pharmingen), anti-CD4-allophycocyanin mAb, anti-CD25-PE mAb. Cells were washed and resuspended in 100 µl of binding buffer in the presence of 1 µl of 7-aminoactinomycin D (7-AAD) to exclude dead cells.

Statistics

Appropriate statistical tests were performed on all data as described in the figure legends using GraphPad Prism version 4.0 software (GraphPad).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Differential effects of CY on lymphoid populations in the NOD mouse

T1D is an autoimmune disease characterized by specific destruction of the insulin-producing β cells of the pancreatic islets of Langerhans. The NOD mouse provides a spontaneous model for T1D, in which ~80% of females and 20% of males develop hyperglycemia by 30 wk of age. Previous studies have established that 40–60% of 10-wk-old male NOD mice, given a single dose of CY, synchronously progress to T1D within 14 days (8). To examine the effects of CY during this critical time, 10-wk-old male NOD mice were given CY (200 mg/kg) and sacrificed 2, 6, and 9 days later for comparison with untreated littermate controls. Lymphocytes were extracted from spleen and PLN as well as the pancreas and analyzed by flow cytometry.

In keeping with previous studies (15, 20, 21), CY treatment caused a significant drop in the number of splenocytes (50%) on day 2 (Fig. 1A). Splenic cellularity remained low on day 6 and then returned or exceeded pretreatment levels on day 9. Similar changes were observed in the PLN (data not shown). CY treatment also resulted in changes in specific cell populations, sharply decreasing CD19+ B cells and, to a lesser extent, CD3+CD4+ T cells and CD3+CD8+ T cells. As a consequence of these differential effects, the percentage of CD4+ and CD8+ T cells was increased (Fig. 1B), whereas the CD4:CD8 ratio remained largely unaltered in all tissues (Fig. 1C). Comparable relative changes were observed in the PLN and pancreas (Fig. 1D).


Figure 1
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 1. CY induced changes in cellular composition of peripheral lymphoid organs. Nondiabetic 10-wk-old male NOD mice were given CY (200 mg/kg) i.p. and sacrificed 2, 6, and 9 days after administration and their cellular composition was compared with untreated controls using flow cytometry. A, Total cell counts of splenic lymphocytes for individual mice. Splenocytes from controls (n = 3/day) were analyzed on days 2, 6, and 9 and are represented as a pooled result. B, Percentages of splenocytes staining for CD19+, CD3+CD4+, and CD3+CD8+. Data points represent arithmetic mean and SEM for combined analysis of individual mice (n = 3). C, Analysis of the CD8+:CD4+ ratio and the CD19+CD4+ ratio (D) was performed in spleen, PLN, and pancreas and are represented as arithmetic means and SEM derived from individual mice (n = 4). Significant differences (p ≤ 0.03, two-sided Mann-Whitney U) from controls are highlighted (*).

 
CY treatment causes loss of CD4+CD25+Foxp3+ Tregs

Further analysis of the CD4+ T cell population indicated a sharp drop in the number of CD4+CD25+ T cells 48 h after CY administration (Fig. 2A). This decline was most marked in the pancreas, where levels of CD4+CD25+ T cells dropped from 22.5 (±1.16%) to 3.3% (±0.1%) corresponding to an overall loss of 85%. However, CD25 is not a unique marker for Tregs (23), but is also found on activated CD4+ T cells. Thus, although the ablation of CD4+CD25+ T cells suggests a loss of Treg cells, it might equally represent an initial loss of activated T cells that also express CD25.


Figure 2
View larger version (24K):
[in this window]
[in a new window]

  		FIGURE 2. Selective changes in the number of CD4+CD25+Foxp3+ Tregs following CY treatment. Nondiabetic 10-wk-old male NOD mice and age-matched C57BL/6 mice were injected i.p. with CY (200 mg/kg), sacrificed 2, 6, and 9 days after administration for comparison with untreated controls. Single-cell suspensions were prepared from spleen, PLN, and pancreas (only NOD) as described. The CD4+ T cell subset from each individual mouse was analyzed for the expression of CD25 or Foxp3 on the different days after treatment. Results are represented as arithmetic means and values for each individual mouse. Data sets marked with (*) indicated significant differences (p ≤ 0.03) as calculated by two-sided Mann-Whitney U test. Results shown are from one experiment, representative of three individual studies. A, Percentages change over time in the proportion of NOD CD4+ T cells expressing CD25. B, Percentages change over time in the proportion of NOD CD4+ T cells expressing Foxp3. C, Percentages change in the proportion of CD4+ T cells expressing CD25 in spleen and PLN of NOD and C57BL/6 mice. D, Relative percentage reduction in the proportion of NOD and C57BL/6 CD4+Foxp3+ T cells after CY treatment standardized to mean percentage expression in each group before treatment, ±95% confidence interval.

 
To confirm the true nature of the affected CD4+CD25+ T cell population, we performed intracellular staining with an Ab against the natural Treg-specific marker Foxp3 (Fig. 2B). Treatment with CY was found markedly to decrease the numbers of CD4+Foxp3+ T cells on day 2 in the spleen, PLN, and most prominently in the pancreas. Foxp3+ T cells were found to be mostly, but not exclusively, CD25+ (data not shown) and recovered to above pretreatment levels in lymphoid organs by day 9. In contrast to CD4+CD25+ cells, CD4+Foxp3+ T cells failed to recover in the pancreas. Taken together, this indicates the loss of Tregs and simultaneous emergence of primed autoreactive CD4+CD25+ T cells within the pancreas, at a time point immediately before T1D onset.

CD4+CD25+Foxp3+ Tregs from NOD mice are not inherently more susceptible to CY-mediated cytotoxicity

The high incidence of T1D in NOD mice after administration of CY (8) is in stark contrast to other mouse strains (20, 21). Therefore, we investigated whether Foxp3+ Tregs from NOD mice are inherently more susceptible to depletion by CY. Age-matched NOD mice and nonautoimmune prone C57BL/6 mice were given CY and analyzed for changes in the percentage of CD4+Foxp3+ T cells. Only lymphoid tissues were compared due to the absence of lymphocytic infiltrates in the pancreas of C57BL/6 mice. Percentages of CD4+Foxp3+ T cells in NOD mice were lower than in the C57BL/6 strain, but both strains displayed a significant drop of the CD4+Foxp3+ T cell subset after administration of CY (Fig. 2C). Normalization of the data showed that both T cell populations are equally affected by CY (Fig. 2D) with more pronounced depletion of CD4+Foxp3+ T cells in the lymph nodes.

CD4+CD25+ Tregs from CY-treated NOD mice display reduced in vitro suppressive activity and increased apoptosis

Previous studies in C57BL/6 (20) and BALB/c mice (21) have shown that CY not only ablates CD4+CD25+ T cells in vivo but can also abrogate their suppressive function in vitro. To verify whether NOD Tregs from CY-treated animals showed a comparable functional impairment, CD4+CD25+ T cells were isolated 48 h after CY dosing and compared with CD4+CD25+ Treg cells from untreated littermate controls. Analysis of the proportions of apoptotic cells stained by annexin V (Fig. 3A) before and after CY treatment showed a significantly greater percentage (11.19 ± 0.83 vs 5.5 ± 0.66%) of apoptotic CD4+CD25+ T cells than CD4+CD25– T cells in the CY-treated group, indicating their greater susceptibility to the drug. CD4+ T cells from untreated controls did not show any significant apoptotic staining (1.04 ± 0.34 vs 1.56 ± 0.54%). Similar findings were made for CD4+CD25+ T cells isolated from PLN (6.06 ± 2.92 vs 1.82 ± 1.17%). When used in an in vitro suppression assay, splenic NOD CD4+CD25+ from CY-treated mice were impaired in their ability to suppress the proliferation of CD4+CD25– T cells from untreated control mice (Fig. 3B). The lack of in vitro suppression was not directly associated with a reduction in the protein expression levels of Foxp3 on a per-cell basis (Fig. 3C).


Figure 3
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 3. Effects of CY on the in vitro suppressor function and apoptosis of NOD CD4+CD25+ Tregs. A, Staining for apoptosis in CD4+ T cells. NOD mice were treated with 200 mg/kg CY i.p. and lymphocytes prepared from spleen and PLN after 48 h for comparison with untreated littermate controls. Whole lymphocytes were stained with Annexin VFITC as described together with CD4 and CD25 surface markers and analyzed by flow cytometry. Cells were initially gated on forward scatter (FSC)/side scatter (SSC) and CD4 expression, excluding all cells staining positive for 7-AAD. A representative FACS dot plot shows the individual gates selecting CD4+CD25– and CD4+CD25+ cells. The percentage of annexin V+ cells was determined as shown in the histogram overlays. Graphs represent the arithmetic means and values for each individual mouse for the percentage of annexin V+ cells. Indicated p values for significance were calculated by two-sided Mann-Whitney U test. B, In vitro CD4+CD25+ Treg suppression assay. CD4+CD25+ T cells were prepared from the pooled spleens of 10-wk-old male NOD mice previously (48 h) treated with 200 mg/kg CY i.p. (n = 6) or their untreated littermate controls (n = 3). These cells were cultured in the presence of 1 x 105 CFSE-labeled CD4+CD25– T cells (Teff) prepared from the spleens of the untreated control mice, at the indicated ratios. A total of 5 x 105 T cell depleted irradiated male NOD splenocytes were added to the cultures, along with 1 µg/ml anti-CD3 mAb. Proliferation of CD4+CD25– T cells was assessed 72 h later by CFSE dilution and by incorporation of [3H]thymidine over the last 12 h of culture. Data points show mean percentage of cells showing CFSE dilution or thymidine incorporation counts ± SEM for triplicate wells. Controls included Teff cells cultured without irradiated splenocytes (No APC) and Teff cells cultured without Tregs (0:1 ratio). *, Significant differences. Data are representative of two repeat experiments. C, Per-cell Foxp3 protein expression in CD4+CD25+ T cells from CY-treated and untreated NOD mice. NOD mice were treated with 200 mg/kg CY i.p. and splenocytes were isolated after 48 h for comparison with untreated littermate controls. Cells were analyzed by flow cytometry gating on the CD4+Foxp3+ population. Data shows representative FACS dot plots from both groups and the graph with the geometric mean fluorescence intensity (GMFI) representing individual data points for each mouse and their arithmetic mean.

 
Adoptive transfer of NOD CD4+CD25+ Tregs suppresses CY-induced T1D

The above results show that onset of T1D in mice given CY is accompanied by a significant drop in the CD4+Foxp3+ Treg population that fails to recover proportionally in the pancreas. Moreover, CD4+CD25+ T cells from CY-treated NOD mice are diminished in their in vitro suppressive activity. We argue that the proportional lack and functional impairment of Tregs after CY treatment might permit progression to T1D. A previous study showed that transfer of a large number of mononuclear cells (5 x 107 over five consecutive days) from nondiabetic syngeneic donors protected CY-treated recipients from T1D onset (15). However, these studies did not identify the cell population responsible for this protection. Therefore, we assessed the ability of purified CD4+CD25+ Treg cells from age-matched nondiabetic NOD donors to protect CY-treated recipients when given 24 h after CY administration. NOD Tregs were purified based on their expression of CD25 and subsequent analysis showed that ~70% of the cells expressed Foxp3 (data not shown). A 24-h time point for adoptive transfers was chosen based on the biological half-life of CY (~30 min) to avoid its toxic effects on the transferred Tregs (25). Fig. 4A illustrates that transfer of 2 x 106 NOD CD4+CD25+ Treg cells reduced the T1D incidence in CY-treated recipient mice, whereas the incidence of T1D in littermates receiving the equivalent number of NOD CD4+CD25– T cells was not altered. Although NOD CD4+CD25+ Tregs consistently lowered T1D incidence in repeat experiments, we noted considerable interexperiment variability, possibly as a result of a low frequency of islet-specific Tregs within the transferred cell population.


Figure 4
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 4. Adoptive transfer of CD4+CD25+ Tregs suppresses CY-induced T1D. Ten- to 12-wk-old male nondiabetic NOD mice were injected i.p. with the indicated dose of CY. Twenty-four hours later, one group received the indicated number of purified CD4+CD25+ T cells from spleens of age-matched NOD (A) or BDC2.5.NOD (B and C) donor mice. Another group received the equivalent number of purified CD4+CD25– T cells from identical donors. A control group did not receive any cells. Mice were then monitored for glycosuria and two successive readings were taken to indicate onset of T1D. Data shown in A are representative of the combined results from two individual experiments with n = 6/group. Results shown in B and C are from single experiments with n = 12 mice/group and are representative of two repeat experiments. Two-sided p values for statistical significance between groups were calculated by Cochran-Mantel-Haenszel testing of the Kaplan-Meier survival curve.

 
Islet Ag-specific CD4+CD25+ Treg cells are highly effective in suppressing CY-accelerated T1D

We next examined whether islet Ag-specific Tregs were more effective in suppressing T1D than polyclonal NOD Tregs. CD4+CD25+ Tregs from TCR transgenic BDC2.5.NOD mice express a TCR specific for an as yet unknown pancreatic islet Ag (26, 27). These cells have been shown to be highly effective in prevention, or even reversal of spontaneous T1D onset in NOD mice (28, 29).

Fig. 4B indicates that adoptive transfer of 1 x 106 BDC2.5. NOD CD4+CD25+ T cells completely prevented the onset of CY-induced T1D. Administration of as few as 1 x 105 Tregs reduced T1D incidence to 8.3% compared with 91% (p = 0.0001) in control recipients (Fig. 4C). In contrast, transfer of purified naive BDC2.5 NOD CD4+CD25– T cells from the same donor mice augmented T1D incidence without significantly affecting the kinetics of T1D development.

Effectiveness of T1D suppression depends on the time between CY administration and transfer of Tregs

To establish the time frame in which effective protection after CY treatment is obtained, we assessed suppression of T1D by BDC2.5.NOD CD4+CD25+ T cells administered at 1, 5, or 8 days after CY treatment. Fig. 5A demonstrates that 2.5 x 105 BDC2.5.NOD Tregs completely suppressed T1D (p = 0.0002) when given 24 h after CY dosing. Adoptive transfer 5 days after CY treatment (Fig. 5B) was still effective (p = 0.0013) in reducing T1D incidence (91 vs 41%) without affecting the kinetics of disease onset. Later transfers of Tregs 8 days after CY dosing failed to significantly affect progression to T1D (Fig. 5C).


Figure 5
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 5. Suppression of CY-induced T1D is dependent on the time interval between CY treatment and transfer of BDC2.5.NOD CD4+CD25+ Tregs. Nondiabetic 13-wk-old male NOD mice were injected i.p. with 250 mg/ml. Individual groups (n = 12) received 2.5 x 105 CD4+CD25+ T cells from age-matched nondiabetic BDC2.5.NOD donors either on days 1 (A), 5 (B), or 8 (C) after CY administration. A corresponding control group did not receive any cells. To achieve homogeneity among BDC2.5.NOD Tregs, these cells were prepared on the same day, but CY was given at the appropriate time points before the adoptive transfers. Mice were monitored for glycosuria and two successive readings were taken to indicate onset of T1D. Two-sided p values for statistical significance from between the groups were calculated by Cochran-Mantel-Haenszel testing of the Kaplan-Meier survival curve.

 
Adoptive transfer of islet Ag-specific BDC2.5.NOD Tregs results in their accumulation and long-term survival within pancreatic islet infiltrates

The above data suggested that CY treatment induces an imbalance between resident CD4+CD25– T cells and naturally occurring CD4+CD25+ Tregs, which ultimately leads to priming of autoreactive T cells and progression to T1D. To further clarify how BDC2.5.NOD Tregs control progression of CY-mediated T1D, we studied the distribution of transferred CD4+Foxp3+ T cells and changes in the activation status of endogenous CD4+ T cells by using GFP-labeled CD4+CD25+ Tregs prepared from GFP. BDC2.5NOD donor mice. Spleen, PLN, and pancreases were analyzed on days 2, 6, and 9 after CY dosing. One group of CY-treated mice was given 2 x 106 GFP+CD4+CD25+ Treg cells (CY plus Treg), whereas the other group served as controls receiving CY only (CY). Interestingly, there were no differences seen between the two groups at any time point in the spleen and PLN in terms of the proportions of CD4+Foxp3+ T cells and CD4+CD62Lhigh cells (data not shown). In contrast, lymphocytes isolated from the pancreas showed that, in keeping with earlier data (Fig. 2B), the diminished proportion of pancreatic CD4+Foxp3+ T cells failed to recover by day 9 in the CY group (Fig. 6A). In the CY plus Treg group, there was a significant increase in the proportion of CD4+Foxp3+ T cells (Fig. 6A; 34.5 ± 3.9 vs 16.1 ± 1.4%). This selective increase of Tregs was mirrored by a lower proportion of activated CD4+ T cells on day 9 (Fig. 6B) and directly correlated with a high proportion of GFP+CD4+ T cells in the pancreas (Fig. 6C).


Figure 6
View larger version (32K):
[in this window]
[in a new window]

  		FIGURE 6. Analysis of CY-mediated changes in T cell activation in the pancreas. Nondiabetic 10-wk-old male NOD mice were injected i.p. with CY (200 mg/kg). Twenty-four hours later, one group received 1 x 106 GFP-labeled CD4+CD25+ Tregs from age-matched GFP.BDC2.5NOD donor mice. Mice from each group were sacrificed 2, 6, and 9 days after administration for comparison with untreated controls. Single-cell suspensions were prepared from spleen, PLN, and pancreas as described. A, Proportion of CD4+ T cells expressing Foxp3 in the pancreas, including GFP+CD4+ T cells. B, Analysis of the proportion of CD4+CD44lowCD62Lhigh. Cells were gated for CD4+GFP– cells only. C, Proportion of CD4+ T cells expressing GFP in Spleen, PLN, and pancreas over time. Representative FACS dot plots are shown (left) as well as graphs with combined results (right). Graphs show arithmetic means and SEM derived from analysis of individual mice (3–4/group/day). *, Data sets with significant differences (p ≤ 0.03) as calculated by two-sided Mann-Whitney U test.

 
To evaluate the long-term fate of adoptively transferred Tregs in protected NOD mice, we analyzed the proportion of CD4+Foxp3+ T cells in the subset of control mice remaining nondiabetic 1 mo after CY treatment and compared these to CY-treated mice which had received 2 x 106 GFP-labeled CD4+CD25+ Tregs from GFP.BDC2.5NOD donor mice. Mice treated with CY alone showed recovered levels of CD4+Foxp3+ T cells equivalent to those seen in untreated control mice (Fig. 7A). However, the CY-Treg group continued to display a significant increase (p = 0.002) in the percentage of CD4+Foxp3+ Treg in the pancreas. Indeed, adoptively transferred Foxp3+GFP+ Tregs could still be detected in spleen, PLN, and the pancreas, but only in the pancreas did they significantly (19 ± 4.1%) contribute to the overall CD4+Foxp3+ Treg population (Fig. 7B). This data supports the idea that Ag-specific Tregs can survive long-term.


Figure 7
View larger version (27K):
[in this window]
[in a new window]

  		FIGURE 7. Transfer of GFP+CD4+CD25+ Tregs in CY-treated NOD mice results in long-term survival and restoration of the pancreatic CD4+Foxp3+ Treg proportions to pretreatment conditions. Nondiabetic 10-wk-old male NOD mice were injected i.p. with CY (250 mg/kg). After 24 h, one group (CY + Treg) received 1 x 106 purified CD4+CD25+ T cells from spleens of age-matched GFP.BDC2.5NOD donors. A control group (CY) did not receive any cells. Incidence of diabetes was determined by testing for glycosuria. After 30 days, single-cell suspensions were prepared from spleen, PLN, and pancreas of all nondiabetic animals, CY-treated mice (CY), and protected mice (CY + Treg) groups and compared with untreated age-matched controls (Control). A, Percentage CD4+ T cells expressing Foxp3. Results are represented as arithmetic means and values for each individual mouse. Significant differences were calculated by two-sided Mann-Whitney U test. B, Contribution of adoptively transferred GFP+CD4+CD25+ Tregs to total proportion of CD4+Foxp3+ T cell population was assessed by analysis of the proportion of CD4+Foxp3+ T cells expressing GFP. Dot plots show representative FACS sample for each organ and one control (pancreas). Graph shows the percentage of GFP+Foxp3+ T cells over total CD4+Foxp3+ population as mean and data points for each individual mouse. Significant differences were calculated by two-sided Mann-Whitney U test.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The paradoxical ability of CY to suppress and enhance immune responses is a long-standing observation. Administration of high-dose CY is usually immunosuppressive and has been used therapeutically in a wide variety of clinical situations. In contrast, administration of a lower dose has been associated with enhanced immune responses which were thought to arise by selective targeting of a suppressor cell population (14). Initial work linking CY with dysregulated T cell responses demonstrated an increase in the immune response in a mouse model of delayed-type hypersensitivity if CY was given before the Ag challenge. Transfer of thymocytes after CY treatment reversed the increase indicating that the anti-suppressor effects of CY are mediated through T cells. Following on from these reports, Harada and Makino (8) proposed that the CY-mediated acceleration of T1D in the NOD mouse is mediated by targeted effects on a suppressor T cell population. The hypothesis that CY selectively ablates suppressor cell activity was also consistent with data from adoptive transfer models where splenocytes from CY-treated NOD mice transferred T1D to irradiated recipients, whereas splenocytes from untreated control mice failed to transfer disease (10). Charlton et al. (15) subsequently demonstrated that acceleration of T1D in NOD mice could be prevented by administration of large numbers of mononuclear cells, although these studies did not identify the protective cell population.

The recent renaissance of suppressor T cells as the more clearly defined CD4+CD25+ or CD4+Foxp3+ Treg population has helped to unravel the role CY in enhancing immune responses. However, no study to date has examined the role of this Treg population in controlling CY-induced autoimmune responses. Previous work has suggested that onset of T1D in NOD mice is due to a general deficiency of Tregs (30, 31). There are also indications that NOD Tregs are functionally impaired, requiring higher cell numbers to suppress ongoing disease than in other autoimmune models (32, 33). Functional evidence for the role of Tregs in preventing T1D has been provided by cell transfer models. Adoptive transfer of isolated islet-infiltrating cells into NOD.scid recipient mice rapidly precipitates T1D, whereas cotransfer with NOD CD4+CD25+ T cells is protective (31). Treatment of NOD mice with neutralizing anti-IL-2 mAb triggers early onset of T1D and a wide spectrum of other T cell-mediated autoimmune diseases (34). Similar to our observations with CY, this neutralization of IL-2 selectively reduces the number of Foxp3-expressing CD4+CD25+ T cells, but not CD4+CD25– T cells.

In rats, mice, and humans, CY treatment is associated with enhanced immune responses suggestive of a direct effect on CD4+CD25+ Tregs (19, 21, 22, 35, 36). Our initial studies in NOD mice confirmed these findings showing that CY preferentially depletes CD4+CD25+ T cells. By using Foxp3 as a more selective marker for naturally occurring Tregs, we showed that the effects of CY on CD4+Foxp3+ cells mirror those seen on CD4+CD25+ T cells providing further support for the argument that CY preferentially affects Tregs.

To establish whether acceleration of T1D was associated with a mouse strain-specific increase in the sensitivity to CY-mediated cytotoxicity, we compared the effects of CY in nonautoimmune C57BL/6 mice. Our data indicate that NOD mice are inherently no more susceptible to CY. As previously shown in nonautoimmune-prone mouse strains (20, 21), we found that CD4+CD25+ Tregs from CY-treated NOD mice displayed reduced in vitro suppressive activity and showed higher proportions of apoptotic cells compared with CD4+CD25– T cells from the same mice. Lutsiak et al. (20) proposed that this greater susceptibility to apoptosis may arise from the higher level of physiological proliferation in response to normal self-Ags. A link between increased apoptosis and T1D induction has also been shown for the CD62Lhigh T cell compartment of NOD mice which is preferentially affected by CY. It is likely that the CD62Lhigh compartment corresponds to CD4+Foxp3+ Tregs. Blockade of the FasL-Fas interaction by administration of Fc-Fas fusion protein to neutralize FasL has been shown to be sufficient to prevent T1D onset by CY and is linked to reduced apoptosis of CD62Lhigh cells (37). Furthermore, the loss of CD62Lhigh or CD4+CD25+ T cells from PLN can be prevented by administration of G-CSF and has been associated with protection from CY-mediated T1D (38, 39). We noted that the selective loss of Foxp3+ Tregs was particularly evident in the pancreas where the proportions of CD4+Foxp3+ T cells before CY administration had been higher than in lymphoid tissues. This large drop in Foxp3+ T cells may result from a lack of survival factors (40). It seems plausible that the rapid loss of islet-specific Tregs may lead to a lack of regulation of autoreactive cells in situ and the onset of diabetes. In support of this, T cell activation markers in the pancreas were increased 9 days after CY administration compared with untreated littermate controls. An alternative, but not mutually exclusive, explanation of the data is that in the lymphopenic environment induced by CY autoreactive T cells expand faster than Tregs, perhaps due to the increased need of the latter population for IL-2 (41, 42, 43).

In this way, following CY, inflammation would outstrip regulation (44, 45). However, the homeostatic proliferative response to lymphopenia does not fully explain why CY can only induce diabetes in NOD mice with established pancreatic infiltration.

Although Tregs isolated from nondiabetic NOD mice could inhibit CY-induced T1D, protection was more significant using Ag-specific Tregs. In support of this, others have shown that transfer of polyclonal CD4+CD25+ Tregs is inefficient and requires infusion of high cell numbers (30, 46). It is now thought that effective suppression of immune responses in vivo by Tregs requires that cells migrate to the appropriate sites, respond to Ag, and survive long term. The effectiveness of Ag-specific Tregs has been recently highlighted and shown to provide a means for an effective therapeutic approach (28, 29). We show here that CD4+CD25+ from TCR-transgenic BDC2.5.NOD mice were highly effective in suppression of T1D when given 24 h after CY treatment. As few as 1 x 105 BDC2.5.NOD Treg cells were sufficient to prevent CY-mediated T1D. Tang et al. (47) have argued that BDC2.5. NOD Tregs exert their regulatory function by interaction with dendritic cells in the PLN which subsequently prevents the priming of naive autoreactive T cells. To assess in vivo changes of CY-treated mice that accompanied injection of BDC2.5.NOD Tregs, we examined lymphoid tissues and pancreases of NOD recipients for T cell activation markers in the presence or absence of GFP-labeled BDC2.5.NOD CD4+CD25+ Tregs. Analysis of lymphoid tissues 6 days after CY treatment suggests that all affected lymphocyte activation marker levels remain low. Priming of autoreactive T cells may not have occurred to any significant extent in the PLN before this time point, which would explain why the transfer of BDC2.5.NOD Tregs 5 days after CY treatment is still able to suppress T1D. The lack of protection by adoptive transfer of BDC2.5.NOD Tregs 8 days after CY administration supports the notion that suppression of priming of autoreactive T cells is necessary to prevent infiltration of pancreatic islets by activated autoreactive T cells. In contrast, spontaneous T1D onset can be reversed when BDC2.5.NOD Tregs are given up to 1 wk after the first signs of glycosuria (28). Our studies indicate that in the CY-accelerated model of T1D BDC2.5.NOD Tregs are only able to control disease if given before diabetes onset. Interestingly, analysis of pancreases from protected mice suggests that although autoreactive T cells are still present within pancreatic infiltrates they may be held in check by the greater proportion of CD4+Foxp3+ T cells. The substantial proportion of GFP+ Tregs within the pancreatic Treg pool 1 mo after CY administration also implies their long-term survival. It remains to be established how resident Tregs mediate their inhibitory function in situ. In this context, it is interesting to note that in vitro-conditioned BDC2.5 Tregs control pancreatic autoreactive T cells by deletion through Fas-FasL interaction (48).

In conclusion, we have shown that CY-induced T1D is associated with a selective apoptotic loss of CD4+CD25+ Treg cells from peripheral lymphoid tissues and the pancreas. Similarly, it has recently been reported that fludarabine, a cytotoxic purine analog, used in treatment of chronic B cell lymphocytic leukemia, also reduces the number and functional activity of circulating Tregs in human patients (19). This raises interesting parallels to the effects reported here with CY. Furthermore, we have shown that the subsequently emerging autoreactive polyclonal T cell response associated with CY administration is effectively controlled by transfer of a low number of islet Ag-specific BDC2.5.NOD CD4+CD25+ T cells. This control may be exerted not only in the PLN as proposed by Tang et al. (47) but also in the pancreas where we could observe the predominant localization of the transferred Tregs as suggested by the studies of Chen et al. (49). We believe that the effectiveness of T1D suppression after CY treatment by a very small number of islet Ag-specific Tregs depends on the additional ablation of activated autoreactive T cells. These studies further highlight the potential of Tregs as a therapeutic means in controlling autoimmune disease.


   Acknowledgments
 
We thank Dr. Jenny Phillips for facilitating these experiments and Dr. Zoltan Fehervari for critical reading of this manuscript.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the Wellcome Trust, Diabetes U.K., and the Isaac Newton Trust of Cambridge. T.R. was funded by Trinity College and the University of Cambridge MB PhD Programme. Back

2 S.B. and T.R. are joint first authors. Back

3 Address correspondence and reprint requests to Dr. Anne Cooke, Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, U.K. E-mail address: ac{at}mole.bio.cam.ac.uk Back

4 Abbreviations used in this paper: CY, cyclophosphamide, T1D, type-1 diabetes; Foxp3, forkhead/winged helix transcription factor; Treg, regulatory T cell; PLN, pancreatic lymph node; 7-AAD, 7-aminoactinomycin D. Back

Received for publication June 5, 2006. Accepted for publication August 22, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Aschan, J., S. Carlens, H. Hagglund, S. Klaesson, J. Mattsson, M. Remberger. 1999. Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up. Clin. Transplant. 13: 512-519. [Medline]
  2. Uchida, S., K. Suzuki, S. Akiyama, M. Miyamoto, T. Juji, M. Fujiwara. 1994. Suppressive effect of cyclophosphamide on the progression of lethal graft-versus-host disease in mice: a therapeutic model of fatal post-transfusion GVHD. Ther. Immunol. 1: 313-318. [Medline]
  3. Polak, L., H. Geleick, J. L. Turk. 1975. Reversal by cyclophosphamide of tolerance in contact sensitization: tolerance induced by prior feeding with DNCB. Immunology 28: 939-942. [Medline]
  4. Glaser, M., R. Lotan. 1979. Augmentation of specific tumor immunity against a syngeneic SV40-induced sarcoma in mice by retinoic acid. Cell Immunol. 45: 175-181. [Medline]
  5. Machiels, J. P., R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye, E. M. Jaffee. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61: 3689-3697. [Abstract/Free Full Text]
  6. MacLean, G. D., D. W. Miles, R. D. Rubens, M. A. Reddish, B. M. Longenecker. 1996. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J. Immunother. Emphasis Tumor. Immunol. 19: 309-316. [Medline]
  7. Vaishampayan, U., J. Abrams, D. Darrah, V. Jones, M. S. Mitchell. 2002. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon {alpha}. Clin. Cancer Res. 8: 3696-3701. [Abstract/Free Full Text]
  8. Harada, M., S. Makino. 1984. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 27: 604-606. [Medline]
  9. Kallen, B., M. Dohlsten, H. Klementsson. 1986. Effect of cyclophosphamide pretreatment on autoimmune encephalomyelitis in rats. Acta Neurol. Scand. 73: 338-344. [Medline]
  10. Yasunami, R., J. F. Bach. 1988. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur. J. Immunol. 18: 481-484. [Medline]
  11. Asherson, G. L., W. Ptak. 1968. Contact and delayed hypersensitivity in the mouse. I. Active sensitization and passive transfer. Immunology 15: 405-416. [Medline]
  12. Maguire, H. C., Jr, V. L. Ettore. 1967. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J. Invest. Dermatol. 48: 39-43. [Medline]
  13. Sullivan, S., P. R. Bergstresser, J. W. Streilein. 1990. Analysis of dose response of trinitrochlorobenzene contact hypersensitivity induction in mice: pretreatment with cyclophosphamide reveals an optimal sensitizing dose. J. Invest. Dermatol. 94: 711-716. [Medline]
  14. Mitsuoka, A., M. Baba, S. Morikawa. 1976. Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice. Nature 262: 77-78. [Medline]
  15. Charlton, B., A. Bacelj, R. M. Slattery, T. E. Mandel. 1989. Cyclophosphamide-induced diabetes in NOD/WEHI mice: evidence for suppression in spontaneous autoimmune diabetes mellitus. Diabetes 38: 441-447. [Abstract]
  16. Rollinghoff, M., A. Starzinski-Powitz, K. Pfizenmaier, H. Wagner. 1977. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J. Exp. Med. 145: 455-459. [Abstract/Free Full Text]
  17. Turk, J. L., D. Parker, L. W. Poulter. 1972. Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide. Immunology 23: 493-501. [Medline]
  18. Turk, J. L., L. W. Poulter. 1972. Selective depletion of lymphoid tissue by cyclophosphamide. Clin. Exp. Immunol. 10: 285-296. [Medline]
  19. Beyer, M., M. Kochanek, K. Darabi, A. Popov, M. Jensen, E. Endl, P. A. Knolle, R. K. Thomas, M. von Bergwelt-Baildon, S. Debey, et al 2005. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106: 2018-2025. [Abstract/Free Full Text]
  20. Lutsiak, M. E., R. T. Semnani, R. De Pascalis, S. V. Kashmiri, J. Schlom, H. Sabzevari. 2005. Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868. [Abstract/Free Full Text]
  21. Ikezawa, Y., M. Nakazawa, C. Tamura, K. Takahashi, M. Minami, Z. Ikezawa. 2005. Cyclophosphamide decreases the number, percentage and the function of CD25+CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. J. Dermatol. Sci. 39: 105-112. [Medline]
  22. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, F. Martin. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344. [Medline]
  23. Fehervari, Z., S. Sakaguchi. 2004. Development and function of CD25+CD4+ regulatory T cells. Curr. Opin. Immunol. 16: 203-208. [Medline]
  24. Sakaguchi, S.. 2004. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562. [Medline]
  25. Sladek, N. E., J. F. Powers, G. M. Grage. 1984. Half-life of oxazaphosphorines in biological fluids. Drug Metab. Dispos. 12: 553-559. [Abstract]
  26. Katz, J. D., B. Wang, K. Haskins, C. Benoist, D. Mathis. 1993. Following a diabetogenic T cell from genesis through pathogenesis. Cell 74: 1089-1100. [Medline]
  27. Haskins, K., M. McDuffie. 1990. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 249: 1433-1436. [Abstract/Free Full Text]
  28. Tang, Q., K. J. Henriksen, M. Bi, E. B. Finger, G. Szot, J. Ye, E. L. Masteller, H. McDevitt, M. Bonyhadi, J. A. Bluestone. 2004. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199: 1455-1465. [Abstract/Free Full Text]
  29. Tarbell, K. V., S. Yamazaki, K. Olson, P. Toy, R. M. Steinman. 2004. CD25+CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199: 1467-1477. [Abstract/Free Full Text]
  30. Salomon, B., D. J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, J. A. Bluestone. 2000. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440. [Medline]
  31. Szanya, V., J. Ermann, C. Taylor, C. Holness, C. G. Fathman. 2002. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J. Immunol. 169: 2461-2465. [Abstract/Free Full Text]
  32. Herbelin, A., J. M. Gombert, F. Lepault, J. F. Bach, L. Chatenoud. 1998. Mature mainstream TCR{alpha}β+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J. Immunol. 161: 2620-2628. [Abstract/Free Full Text]
  33. Lepault, F., M. C. Gagnerault. 2000. Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice. J. Immunol. 164: 240-247. [Abstract/Free Full Text]
  34. Setoguchi, R., S. Hori, T. Takahashi, S. Sakaguchi. 2005. Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201: 723-735. [Abstract/Free Full Text]
  35. Taieb, J., N. Chaput, N. Schartz, S. Roux, S. Novault, C. Menard, F. Ghiringhelli, M. Terme, A. F. Carpentier, G. Darrasse-Jese, et al 2006. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176: 2722-2729. [Abstract/Free Full Text]
  36. Di Paolo, N. C., S. Tuve, S. Ni, K. E. Hellstrom, I. Hellstrom, A. Lieber. 2006. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res. 66: 960-969. [Abstract/Free Full Text]
  37. Mahiou, J., U. Walter, F. Lepault, F. Godeau, J. F. Bach, L. Chatenoud. 2001. In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice. J. Autoimmun. 16: 431-440. [Medline]
  38. Hadaya, K., H. Kared, A. Masson, L. Chatenoud, F. Zavala. 2005. G-CSF treatment prevents cyclophosphamide acceleration of autoimmune diabetes in the NOD mouse. J. Autoimmun. 24: 125-134. [Medline]
  39. Kared, H., A. Masson, H. Adle-Biassette, J. F. Bach, L. Chatenoud, F. Zavala. 2005. Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4+CD25+ regulatory T-cells. Diabetes 54: 78-84. [Abstract/Free Full Text]
  40. Fontenot, J. D., J. P. Rasmussen, M. A. Gavin, A. Y. Rudensky. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6: 1142-1151. [Medline]
  41. Fehervari, Z., T. Yamaguchi, S. Sakaguchi. 2006. The dichotomous role of IL-2: tolerance versus immunity. Trends Immunol. 27: 109-111. [Medline]
  42. Knoechel, B., J. Lohr, E. Kahn, J. A. Bluestone, A. K. Abbas. 2005. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J. Exp. Med. 202: 1375-1386. [Abstract/Free Full Text]
  43. Malek, T. R., A. L. Bayer. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4: 665-674. [Medline]
  44. Matos, M., R. Park, D. Mathis, C. Benoist. 2004. Progression to islet destruction in a cyclophosphamide-induced transgenic model: a microarray overview. Diabetes 53: 2310-2321. [Abstract/Free Full Text]
  45. Rothe, H., A. Faust, U. Schade, R. Kleemann, G. Bosse, T. Hibino, S. Martin, H. Kolb. 1994. Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-{gamma}, but not of interleukin-4. Diabetologia 37: 1154-1158. [Medline]
  46. Gregori, S., N. Giarratana, S. Smiroldo, L. Adorini. 2003. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J. Immunol. 171: 4040-4047. [Abstract/Free Full Text]
  47. Tang, Q., J. Y. Adams, A. J. Tooley, M. Bi, B. T. Fife, P. Serra, P. Santamaria, R. M. Locksley, M. F. Krummel, J. A. Bluestone. 2006. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. 7: 83-92. [Medline]
  48. Weber, S. E., J. Harbertson, E. Godebu, G. A. Mros, R. C. Padrick, B. D. Carson, S. F. Ziegler, L. M. Bradley. 2006. Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J. Immunol. 176: 4730-4739. [Abstract/Free Full Text]
  49. Chen, Z., A. E. Herman, M. Matos, D. Mathis, C. Benoist. 2005. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J. Exp. Med. 202: 1387-1397. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 JEMHome page
D. Hirschhorn-Cymerman, G. A. Rizzuto, T. Merghoub, A. D. Cohen, F. Avogadri, A. M. Lesokhin, A. D. Weinberg, J. D. Wolchok, and A. N. Houghton
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
J. Exp. Med., May 11, 2009; 206(5): 1103 - 1116.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. R. Rigby, A. M. Trexler, T. C. Pearson, and C. P. Larsen
CD28/CD154 Blockade Prevents Autoimmune Diabetes by Inducing Nondeletional Tolerance After Effector T-Cell Inhibition and Regulatory T-Cell Expansion
Diabetes, October 1, 2008; 57(10): 2672 - 2683.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
Y. Mori, T. Kato, T. Kodaka, E. M. Kanagawa, S. Hori, and O. Kanagawa
Protection of IFN-{gamma} signaling-deficient NOD mice from diabetes by cyclophosphamide
Int. Immunol., September 1, 2008; 20(9): 1231 - 1237.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. E. Clough, C. J. Wang, E. M. Schmidt, G. Booth, T. Z. Hou, G. A. Ryan, and L. S. K. Walker
Release from Regulatory T Cell-Mediated Suppression during the Onset of Tissue-Specific Autoimmunity Is Associated with Elevated IL-21
J. Immunol., April 15, 2008; 180(8): 5393 - 5401.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Calzascia, M. Pellegrini, A. Lin, K. M. Garza, A. R. Elford, A. Shahinian, P. S. Ohashi, and T. W. Mak
CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity
PNAS, February 26, 2008; 105(8): 2999 - 3004.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brode, S.
Right arrow Articles by Cooke, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brode, S.
Right arrow Articles by Cooke, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CYCLOPHOSPHAMIDE
Medline Plus Health Information
*Diabetes Type 1

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS